Analyst Price Targets — LBRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 10:01 am | Rudy Li | Wolfe Research | $45.00 | $33.41 | TheFly | LB Pharmaceuticals initiated with an Outperform at Wolfe Research |
| May 17, 2026 11:35 pm | — | Roth Capital | $37.00 | $29.66 | TheFly | LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital |
| April 27, 2026 10:13 am | — | H.C. Wainwright | $45.00 | $30.73 | TheFly | LB Pharmaceuticals initiated with a Buy at H.C. Wainwright |
| April 10, 2026 1:13 pm | — | Craig-Hallum | $36.00 | $24.69 | TheFly | Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy |
| March 27, 2026 10:16 am | — | Stifel Nicolaus | $40.00 | $23.84 | TheFly | LB Pharmaceuticals price target raised to $40 from $35 at Stifel |
| January 9, 2026 9:26 am | — | Roth Capital | $31.00 | $20.80 | TheFly | LB Pharmaceuticals initiated with a Buy at Roth Capital |
| December 11, 2025 12:23 pm | — | Stifel Nicolaus | $35.00 | $21.36 | TheFly | LB Pharmaceuticals price target raised to $35 from $27 at Stifel |
| October 6, 2025 10:15 am | — | Leerink Partners | $34.00 | $15.05 | TheFly | LB Pharmaceuticals initiated with an Outperform at Leerink |
| October 6, 2025 9:15 am | — | Stifel Nicolaus | $27.00 | $15.05 | TheFly | LB Pharmaceuticals initiated with a Buy at Stifel |
Latest News for LBRX
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on…
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations.…
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following…
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LBRX.
Senate Trading
No Senate trades found for LBRX.
U.S. House Trading
No House trades found for LBRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.